GRDN Stock Forecast & Price Target

Guardian Pharmacy Service is viewed favorably because it is the clear ALF-focused leader in a fragmented long-term care pharmacy market, with 13% national share, strong scale, and proprietary technology that improves adherence, payer relationships, and operating efficiency. Its outlook is further supported by durable secular demand as baby boomers age into assisted living, with the 80+ population expected to grow at a mid-single-digit rate and the company’s three-pronged organic strategy positioned to sustain high-single-digit growth over the long term. The balance sheet and acquisition pipeline add upside, as ~$90M of cash, no debt, and an untapped $40M revolver support M&A, while 2024 and 2025 pharmacy cohorts representing ~10% of revenue could contribute a 3-4% EBITDA tailwind in 2027 and 2028.

Guardian Pharmacy Service is facing a structurally weaker reimbursement backdrop as the IRA compresses LTC pharmacy margins by limiting payment to the MFP plus a dispensing fee, which can still sit below acquisition cost even after manufacturer true-ups. The negative outlook is also reinforced by sector-wide regulatory overhangs, including Medicare and Medicaid exposure and uncertainty around drug pricing, PBM contracts, and reimbursement rates, all of which can pressure profitability and cash generation. In addition, the Omnicare bankruptcy in September 2025 underscores the legal and compliance risks in the LTC pharmacy model, while operational execution risks such as labor shortages and integrating acquired facilities add further strain.